Should I buy or sell uniQure stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" QURE shares. View QURE analyst ratings or view top-rated stocks .

What is uniQure's stock price target for 2024?

7 equities research analysts have issued 1-year price targets for uniQure's shares. Their QURE share price targets range from $7.00 to $56.00. On average, they anticipate the company's stock price to reach $32.00 in the next year. This suggests a possible upside of 579.4% from the stock's current price. View analysts price targets for QURE or view top-rated stocks among Wall Street analysts .

How have QURE shares performed in 2024?

uniQure's stock was trading at $6.77 on January 1st, 2024. Since then, QURE shares have decreased by 30.4% and is now trading at $4.71. View the best growth stocks for 2024 here .

Are investors shorting uniQure?

uniQure saw a decline in short interest in March. As of March 31st, there was short interest totaling 2,480,000 shares, a decline of 51.8% from the March 15th total of 5,150,000 shares. Based on an average trading volume of 1,040,000 shares, the days-to-cover ratio is presently 2.4 days. Currently, 5.8% of the shares of the stock are sold short. View uniQure's Short Interest .

When is uniQure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our QURE earnings forecast .

How were uniQure's earnings last quarter?

uniQure (NASDAQ:QURE) issued its quarterly earnings results on Wednesday, February, 28th. The biotechnology company reported ($1.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.54) by $0.01. The biotechnology company earned $6.69 million during the quarter, compared to the consensus estimate of $3.20 million. uniQure had a negative trailing twelve-month return on equity of 99.31% and a negative net margin of 1,947.09%.

What ETF holds uniQure's stock?

Global X Genomics & Biotechnology ETF holds 100,751 shares of QURE stock, representing 0.69% of its portfolio.

What is Matthew Kapusta's approval rating as uniQure's CEO?

8 employees have rated uniQure Chief Executive Officer Matthew Kapusta on Glassdoor.com . Matthew Kapusta has an approval rating of 74% among the company's employees.

What other stocks do shareholders of uniQure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY) , Micron Technology (MU) , Gilead Sciences (GILD) , Alibaba Group (BABA) , AbbVie (ABBV) , GW Pharmaceuticals (GWPH) , NVIDIA (NVDA) , Exelixis (EXEL) , Block (SQ) and bluebird bio (BLUE) .

How do I buy shares of uniQure?

Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:QURE

uniQure (QURE) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free QURE Stock Alerts

$4.71

+0.04 (+0.86%)

(As of 05:32 PM ET)

Compare

Today's Range: $4.66
▼
$4.76
50-Day Range: $4.67
▼
$6.75
52-Week Range: $4.61
▼
$22.48

Volume: 440,747 shs
Average Volume: 1.00 million shs
Market Capitalization: $225.33 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $32.00

Get uniQure alerts:

uniQure MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.71 Rating Score
Upside/Downside: 579.4% Upside
$32.00 Price Target
Short Interest: Healthy
5.83% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$339,845 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($4.49) to ($4.17) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.89 out of 5 stars

Medical Sector

588th out of 919 stocks

Pharmaceutical Preparations Industry

253rd out of 405 stocks

3.4

Analyst's Opinion

Consensus Rating
uniQure has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.
Amount of Analyst Coverage
uniQure has only been the subject of 3 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
5.83% of the float of uniQure has been sold short.
Short Interest Ratio / Days to Cover
uniQure has a short interest ratio ("days to cover") of 2.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in uniQure has recently decreased by 51.84%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
uniQure does not currently pay a dividend.
Dividend Growth
uniQure does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for QURE.

0.0

News and Social Media Coverage

Search Interest
Only 4 people have searched for QURE on MarketBeat in the last 30 days. This is a decrease of -69% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added uniQure to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, uniQure insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $339,845.00 in company stock.
Percentage Held by Insiders
Only 4.05% of the stock of uniQure is held by insiders.
Percentage Held by Institutions
78.83% of the stock of uniQure is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for uniQure are expected to grow in the coming year, from ($4.49) to ($4.17) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of uniQure is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of uniQure is -0.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
uniQure has a P/B Ratio of 1.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About uniQure Stock (NASDAQ:QURE)

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

QURE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

QURE Stock News Headlines

April 9, 2024 | americanbankingnews.com

uniQure (NASDAQ:QURE) Receives Consensus Recommendation of "Moderate Buy" from Analysts

February 28, 2024 | globenewswire.com

uniQure Announces 2023 Financial Results and Highlights Recent Company Progress

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

July 17, 2023 | seekingalpha.com

uniQure: The AMT-130 Readout

May 22, 2023 | seekingalpha.com

Market Is Still Not Pricing In The FDA And EU EMA Approvals For uniQure

May 20, 2023 | seekingalpha.com

uniQure: Financials And Pipeline Signal A Promising Outlook For Investors

February 7, 2022 | globenewswire.com

uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington's Disease - GlobeNewswire

February 7, 2022 | finance.yahoo.com

uniQure Announces Dosing of First Patients in European Open-Label Clinical Trial of AMT-130 Gene Therapy in Huntington’s Disease

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

February 5, 2022 | washingtonpost.com

With CRISPR gene editing, unique treatments begin to take off for rare diseases - The Washington Post

February 4, 2022 | finance.yahoo.com

Global Gene Therapy for Blood Disorders Market worth US$ 5.79 Billion by 2030 - Exclusive Report by InsightAce Analytic - Yahoo Finance

February 4, 2022 | marketscreener.com

EAHAD 2022 - Final Analysis from the Pivotal Phase 3 HOPE-B Gene Therapy Trial: Stable Steady-State Efficacy and Safety of Etranacogene Dezaparvovec in Adults with Sever or Moderately Severe Hemophilia B - Marketscreener.com

February 4, 2022 | axios.com

5 unique date ideas in NW Arkansas - Axios

February 4, 2022 | reuters.com

Amazon has a unique inflation problem - Reuters

February 3, 2022 | chicago.suntimes.com

Bears hope Justin Fields ‘skyrockets’ — but his rookie struggles weren’t unique - Chicago Sun-Times

February 3, 2022 | washingtonpost.com

Turkey's Recep Tayyip Erdogan is the latest leader to visit Ukraine - The Washington Post

February 3, 2022 | nj.com

Unique soap shop franchise to make N.J. debut - NJ.com

February 2, 2022 | forbes.com

Looking To Fill Unique Sports Merchandise Void, ‘Official League’ Launches Lifestyle Brand - Forbes

February 2, 2022 | bbc.com

Deliberate infections give unique Covid insight - BBC News

January 31, 2022 | pymnts.com

What Makes the UE’s Digital Markets Act Unique - pymnts.com

January 31, 2022 | patriotswire.usatoday.com

Bill Belichick has unique hiring opportunities if everyone swallows their pride - Patriots Wire

January 31, 2022 | nj.com

Chicken-filled waffle cones are coming to N.J. at this unique new eatery - NJ.com

January 31, 2022 | abcnews.go.com

Review: Unique narrator propels 'What the Fireflies Knew' - ABC News

January 31, 2022 | globenewswire.com

UNIUM Produces Unique Influencer NFT in Its Marketplace - GlobeNewswire

January 28, 2022 | saintswire.usatoday.com

How Sean Payton helped save the Saints, and build a unique bond with fans - Saints Wire

January 27, 2022 | forbes.com

Small Business Owners Have A Truly Unique Roth Contribution Opportunity! - Forbes

January 27, 2022 | nj.com

Burlington County Open wrestling tournament unique in South Jersey - nj.com

See More Headlines

Receive QURE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for uniQure and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:QURE
CUSIP: N/A
CIK: 1590560
Web: www.uniqure.com
Phone: (120) 240-6000
Fax: 31-20-566-9272
Employees: 480
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $32.00
High Stock Price Target: $56.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +585.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.71
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($6.48)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-308,480,000.00
Net Margins: -1,947.09%
Pretax Margin: -1,934.97%
Return on Equity: -99.31%
Return on Assets: -37.65%

Debt

Debt-to-Equity Ratio: 0.49
Current Ratio: 8.85
Quick Ratio: 8.68

Sales & Book Value

Annual Sales: $15.84 million
Price / Sales: 14.10
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.34 per share
Price / Book: 1.08

Miscellaneous

Outstanding Shares: 47,840,000
Free Float: 45,901,000
Market Cap: $223.41 million
Optionable: Optionable
Beta: 0.95

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Matthew Craig Kapusta (Age 52)
CEO & Executive Director
Comp: $1.16M
Mr. Christian Klemt (Age 51)
CFO, Principal Financial Officer & GM of Amsterdam Site
Comp: $566.36k
Mr. Pierre Caloz (Age 52)
Chief Operating Officer
Comp: $951.1k
Prof. Hugo Katus
Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
Mr. Richard Porter Ph.D.
Chief Business & Scientific Officer
Dr. Jeannette Potts J.D. (Age 62)
Ph.D., Chief Legal & Compliance Officer
Dr. Tamara Tugal Ph.D.
MBA, Business Development Director
Ms. Carla Poulson
Interim Chief People and Culture Officer
Ms. Maria E. Cantor (Age 56)
Chief Corporate Affairs Officer
Comp: $491.12k
Dr. Amin Abujoub Ph.D.
Chief Quality Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

QURE Stock Analysis - Frequently Asked Questions

Should I buy or sell uniQure stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for uniQure in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" QURE shares.
View QURE analyst ratings or view top-rated stocks.
What is uniQure's stock price target for 2024?: 7 equities research analysts have issued 1-year price targets for uniQure's shares. Their QURE share price targets range from $7.00 to $56.00. On average, they anticipate the company's stock price to reach $32.00 in the next year. This suggests a possible upside of 579.4% from the stock's current price.
View analysts price targets for QURE or view top-rated stocks among Wall Street analysts.
How have QURE shares performed in 2024?: uniQure's stock was trading at $6.77 on January 1st, 2024. Since then, QURE shares have decreased by 30.4% and is now trading at $4.71.
View the best growth stocks for 2024 here.
Are investors shorting uniQure?: uniQure saw a decline in short interest in March. As of March 31st, there was short interest totaling 2,480,000 shares, a decline of 51.8% from the March 15th total of 5,150,000 shares. Based on an average trading volume of 1,040,000 shares, the days-to-cover ratio is presently 2.4 days. Currently, 5.8% of the shares of the stock are sold short.
View uniQure's Short Interest.
When is uniQure's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our QURE earnings forecast.
How were uniQure's earnings last quarter?: uniQure (NASDAQ:QURE) issued its quarterly earnings results on Wednesday, February, 28th. The biotechnology company reported ($1.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.54) by $0.01. The biotechnology company earned $6.69 million during the quarter, compared to the consensus estimate of $3.20 million. uniQure had a negative trailing twelve-month return on equity of 99.31% and a negative net margin of 1,947.09%.

What ETF holds uniQure's stock?: Global X Genomics & Biotechnology ETF holds 100,751 shares of QURE stock, representing 0.69% of its portfolio.
What is Matthew Kapusta's approval rating as uniQure's CEO?: 8 employees have rated uniQure Chief Executive Officer Matthew Kapusta on Glassdoor.com. Matthew Kapusta has an approval rating of 74% among the company's employees.
What other stocks do shareholders of uniQure own?: Based on aggregate information from My MarketBeat watchlists, some companies that other uniQure investors own include Empire Resorts (NYNY), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), AbbVie (ABBV), GW Pharmaceuticals (GWPH), NVIDIA (NVDA), Exelixis (EXEL), Block (SQ) and bluebird bio (BLUE).
How do I buy shares of uniQure?: Shares of QURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:QURE) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial